SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. You have free access to this content1
    Nobutaka Hattori, Hiroshi Nishioka, Kazuko Hasegawa, Comparison of ropinirole controlled- and immediate-release in Japanese patients with advanced Parkinson's disease, Neurology and Clinical Neuroscience, 2015, 3, 1
  2. 2
    Fabrizio Stocchi, Laura Vacca, Fabiana G Radicati, How to optimize the treatment of early stage Parkinson’s disease, Translational Neurodegeneration, 2015, 4, 1, 4

    CrossRef

  3. 3
    Heinz Reichmann, Modern treatment in Parkinson’s disease, a personal approach, Journal of Neural Transmission, 2015,

    CrossRef

  4. 4
    A. Alonso Cánovas, R. Luquin Piudo, P. García Ruiz-Espiga, J.A. Burguera, V. Campos Arillo, A. Castro, G. Linazasoro, J. López del Val, L. Vela, J.C. Martínez Castrillo, Agonistas dopaminérgicos en la enfermedad de Parkinson, Neurología, 2014, 29, 4, 230

    CrossRef

  5. 5
    Fabio Blandini, Marie-Therese Armentero, Dopamine receptor agonists for Parkinson's disease, Expert Opinion on Investigational Drugs, 2014, 23, 3, 387

    CrossRef

  6. 6
    A. Alonso Cánovas, R. Luquin Piudo, P. García Ruiz-Espiga, J.A. Burguera, V. Campos Arillo, A. Castro, G. Linazasoro, J. López Del Val, L. Vela, J.C. Martínez Castrillo, Dopaminergic agonists in Parkinson's disease, Neurología (English Edition), 2014, 29, 4, 230

    CrossRef

  7. 7
    Fabrizio Stocchi, Fabiana G Radicati, Margherita Torti, Drug safety evaluation of ropinirole prolonged release, Expert Opinion on Drug Safety, 2014, 13, 3, 383

    CrossRef

  8. 8
    Job F. M. van Boven, Annoesjka Novak, Maurice T. Driessen, Cornelis Boersma, Maarten M. Boomsma, Maarten J. Postma, Economic Evaluation of Ropinirole Prolonged Release for Treatment of Parkinson’s Disease in The Netherlands, Drugs & Aging, 2014, 31, 3, 193

    CrossRef

  9. 9
    Eva Schaeffer, Andrea Pilotto, Daniela Berg, Pharmacological Strategies for the Management of Levodopa-Induced Dyskinesia in Patients with Parkinson’s Disease, CNS Drugs, 2014, 28, 12, 1155

    CrossRef

  10. 10
    Rajesh Pahwa, Kelly E. Lyons, Treatment of early Parkinsonʼs disease, Current Opinion in Neurology, 2014, 27, 4, 442

    CrossRef

  11. 11
    Tetsuya Maeda, Clinical experiences of the Japanese treatment guideline on Parkinson’s disease, Rinsho Shinkeigaku, 2013, 53, 11, 1348

    CrossRef

  12. 12
    Brenton A Wright, Cheryl H Waters, Continuous dopaminergic delivery to minimize motor complications in Parkinson’s disease, Expert Review of Neurotherapeutics, 2013, 13, 6, 719

    CrossRef

  13. 13
    Maria Papathanou, Rika Laan, Peter Jenner, Sarah Rose, Andrew C. McCreary, Levodopa infusion does not decrease the onset of abnormal involuntary movements in parkinsonian rats, Movement Disorders, 2013, 28, 8
  14. 14
    K. Ray Chaudhuri, Alexandra Rizos, Kapil D. Sethi, Motor and nonmotor complications in Parkinson’s disease: an argument for continuous drug delivery?, Journal of Neural Transmission, 2013, 120, 9, 1305

    CrossRef

  15. You have free access to this content15
    J. J. Ferreira, R. Katzenschlager, B. R. Bloem, U. Bonuccelli, D. Burn, G. Deuschl, E. Dietrichs, G. Fabbrini, A. Friedman, P. Kanovsky, V. Kostic, A. Nieuwboer, P. Odin, W. Poewe, O. Rascol, C. Sampaio, M. Schüpbach, E. Tolosa, C. Trenkwalder, A. Schapira, A. Berardelli, W. H. Oertel, Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease, European Journal of Neurology, 2013, 20, 1
  16. 16
    C. Ossig, H. Reichmann, Treatment of Parkinson’s disease in the advanced stage, Journal of Neural Transmission, 2013, 120, 4, 523

    CrossRef

  17. 17
    Nicola Tambasco, Simone Simoni, Erica Marsili, Elisa Sacchini, Donatella Murasecco, Gabriela Cardaioli, Aroldo Rossi, Paolo Calabresi, Clinical Aspects and Management of Levodopa-Induced Dyskinesia, Parkinson's Disease, 2012, 2012, 1

    CrossRef

  18. 18
    J. Guridi, R. González-Redondo, J. A. Obeso, Clinical Features, Pathophysiology, and Treatment of Levodopa-Induced Dyskinesias in Parkinson’s Disease, Parkinson's Disease, 2012, 2012, 1

    CrossRef

  19. 19
    Graeme JA Macphee, David A Stewart, Parkinson's disease: treatment and non-motor features, Reviews in Clinical Gerontology, 2012, 22, 04, 243

    CrossRef

  20. 20
    Maria Cruz Rodriguez-Oroz, Concepción Marin, Oriol de Fabregues, Continuous Dopaminergic Stimulation, The Neurologist, 2011, 17, S30

    CrossRef

  21. 21
    Fabrizio Stocchi, Continuous dopaminergic stimulation and novel formulations of dopamine agonists, Journal of Neurology, 2011, 258, S2, 316

    CrossRef

  22. 22
    Kelly E. Lyons, Rajesh Pahwa, Diagnosis and Initiation of Treatment in Parkinson's Disease, International Journal of Neuroscience, 2011, 121, S2, 27

    CrossRef

  23. 23
    H.H. Fernandez, P. Odin, Levodopa–carbidopa intestinal gel for treatment of advanced Parkinson’s disease, Current Medical Research and Opinion, 2011, 27, 5, 907

    CrossRef

  24. 24
    Olivier Rascol, Andres Lozano, Matthew Stern, Werner Poewe, Milestones in Parkinson's disease therapeutics, Movement Disorders, 2011, 26, 6
  25. 25
    Mark Sanford, Lesley J. Scott, Rotigotine Transdermal Patch, CNS Drugs, 2011, 25, 8, 699

    CrossRef

  26. 26
    Mark Sanford, Lesley J. Scott, Spotlight on Rotigotine Transdermal Patch in Parkinsonʼs Disease†, Drugs & Aging, 2011, 28, 12, 1015

    CrossRef

  27. 27
    Susan H. Fox, Regina Katzenschlager, Shen-Yang Lim, Bernard Ravina, Klaus Seppi, Miguel Coelho, Werner Poewe, Olivier Rascol, Christopher G. Goetz, Cristina Sampaio, The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease, Movement Disorders, 2011, 26, S3
  28. 28
    Mildred D. Gottwald, Michael J. Aminoff, Therapies for dopaminergic-induced dyskinesias in parkinson disease, Annals of Neurology, 2011, 69, 6
  29. 29
    Ainhi D. Ha, Joseph Jankovic, Pathophysiology, Pharmacology, and Biochemistry of Dyskinesia, 2011,

    CrossRef